Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01130662 · ClinicalTrials.gov registry record · Phase 1
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by University of Kansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01130662 is a Phase 1 study that has completed, run by University of Kansas. The registered enrollment target is 16 participants.
The verdict
NCT01130662, a Phase 1 study, has completed, sponsored by University of Kansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the tolerated dose of the combination of decitabine and midostaurin as induction (first cycle of chemotherapy) and consolidation (additional chemotherapy once a patient goes into remission) in people greater than 60 years with newly diagnosed AML or adult patients with relapsed/refractory disease.
Interventions
- DRUG combination therapy using decitabine and midostaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01130662
The ClinicalTrials.gov registry entry for NCT01130662 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which combination therapy using decitabine and midostaurin is the first listed.
NCT01130662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01130662 about?
NCT01130662 is a clinical study titled "Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia". The purpose of this study is to determine the tolerated dose of the combination of decitabine and midostaurin as induction (first cycle of chemotherapy) and consolidation (additional chemotherapy once a patient goes into remission) in people greater than 60 years with newly diagnosed AML or adult pa...
What is the current status of trial NCT01130662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2010-03. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01130662?
The interventions under investigation include: combination therapy using decitabine and midostaurin (DRUG).
Who is sponsoring clinical trial NCT01130662?
This trial is sponsored by University of Kansas, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.